Wedbush upgraded shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) from a neutral rating to an outperform rating in a report released on Tuesday morning, MarketBeat.com reports. They currently have $6.00 target price on the stock, up from their prior target price of $5.00. Other analysts also recently issued research reports about the company. HC […]